Sudarshan Pharma Industries Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹217 Cr +28.5% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
SP

Sudarshan Pharma Industries Ltd

Q1 FY27Chemicals & Petrochemicals

Sudarshan Pharma Industries Q1 FY27: Revenue ₹174.41 Cr, PAT ₹5.61 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹174Cr
+20.1% YoY
−21% QoQ
Net profit
₹6Cr
+41.7% YoY
−50.8% QoQ
Margin
9.12%
+1.5 pp YoY
0 pp QoQ

Sudarshan Pharma Industries Ltd Q1 FY27 key numbers

Revenue
Revenue from Operations for June 2026 quarter: ₹174.41 Cr.

As stated in Sudarshan Pharma Industries Ltd's Q1 FY27 investor presentation · published 25 Sept 2026. Reported figures, not investment advice.

Based on Sudarshan Pharma Industries Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹39
Market cap₹990 Cr
P/E39.4

The short version

Revenue from Operations for June 2026 quarter: ₹174.41 Cr (Page 39) - Revenue from Operations for June 2025 quarter: ₹145.26 Cr - Year-on-year (YoY) revenue growth for the quarter: ₹174.41 Cr vs ₹145.26 Cr (~20.1% increase) - Gross Profit Margin for June 2026 quarter: 14.13% (up from 11.05% in June 2025) - EBITDA Margin for June 2026 quarter: 9.81% (up from 8.43% in June 2025) - Explicit revenue outlook for FY 26-27: Target minimum export turnover of ₹100 Cr (Page 13) - Plans to strengthen API product range, increase focus on regulated and semi-regulated markets including Europe and USA - For June 2026 quarter (unaudited): - EBITDA: ₹17.11 Cr (up from ₹12.25 Cr in June 2025) → +39.7% YoY - EBITDA Margin: 9.81% (up from 8.43% in June 2025) - Profit after Tax (PAT): ₹5.61 Cr (up from ₹3.96 Cr in June 2025) → +41.7% YoY - PAT Margin: 3.21% (up from 2.72% in June 2025) - Yearly figures (FY26 vs FY25) show: - Operating EBITDA: ₹49.3 Cr (vs ₹39.9 Cr in FY25) → +23.6% - PAT: ₹23.3 Cr (FY26) vs ₹15.1 Cr (FY25) → +54.3% - PAT Margin improved accordingly.

From Sudarshan Pharma Industries Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Revenue from Operations for June 2026 quarter: ₹174.41 Cr (Page 39)
  • Revenue from Operations for June 2025 quarter: ₹145.26 Cr
  • Year-on-year (YoY) revenue growth for the quarter: ₹174.41 Cr vs ₹145.26 Cr (~20.1% increase)
  • Gross Profit Margin for June 2026 quarter: 14.13% (up from 11.05% in June 2025)
  • EBITDA Margin for June 2026 quarter: 9.81% (up from 8.43% in June 2025)

2 more points from Sudarshan Pharma Industries Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Sudarshan Pharma Industries Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Nutraceuticals Plant project with a cost of Rs. 2.5 Cr and machinery cost of Rs. 1.15 Cr (2019-2020).
  • Erection of oral liquid and capsule manufacturing unit at Palghar (2021-2022).
  • Developing new products like Vitamin B1 and B6 under production-linked incentive (PLI) schemes (2021-2022).
  • New unit development in Palghar (2023-2024).

2 more points from Sudarshan Pharma Industries Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sudarshan Pharma Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Sudarshan Pharma Industries Ltd said on order book & pipeline — free account, 30 seconds.

Sudarshan Pharma Industries Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Sudarshan Pharma Industries Ltd Q1 FY27 results — key figures

Sudarshan Pharma Industries Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue174145+20.1%221-21%
Operating profit (EBITDA)1611+44%20-21.3%
Operating margin9.12%7.6%+1.5 pp9.14%0 pp
Profit before tax85+38.6%16-52.3%
Net profit (PAT)64+41.7%11-50.8%
EPS (₹)0.230.17+35.3%0.45-48.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Sudarshan Pharma's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Alufluoride (Q1 FY27)

    Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr

  • POCL Enterprises (Q1 FY27)

    466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto

  • Devson Catalyst (Q1 FY27)

    FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee

  • Ambani Orgochem (Q1 FY27)

    Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sudarshan Pharma Industries Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sudarshan Pharma Industries Ltd Q1 FY27 results?

Revenue from Operations for June 2026 quarter: ₹174.41 Cr (Page 39) - Revenue from Operations for June 2025 quarter: ₹145.26 Cr - Year-on-year (YoY) revenue growth for the quarter: ₹174.41 Cr vs ₹145.26 Cr (~20.1% increase) - Gross Profit Margin for June 2026 quarter: 14.13% (up from 11.05% in June 2025) - EBITDA Margin for June 2026 quarter: 9.81% (up from 8.43% in June 2025) - Explicit revenue outlook for FY 26-27: Target minimum export turnover of ₹100 Cr (Page 13) - Plans to strengthen API product range, increase focus on regulated and semi-regulated markets including Europe and USA - For June 2026 quarter (unaudited): - EBITDA: ₹17.11 Cr (up from ₹12.25 Cr in June 2025) → +39.7% YoY - EBITDA Margin: 9.81% (up from 8.43% in June 2025) - Profit after Tax (PAT): ₹5.61 Cr (up from ₹3.96 Cr in June 2025) → +41.7% YoY - PAT Margin: 3.21% (up from 2.72% in June 2025) - Yearly figures (FY26 vs FY25) show: - Operating EBITDA: ₹49.3 Cr (vs ₹39.9 Cr in FY25) → +23.6% - PAT: ₹23.3 Cr (FY26) vs ₹15.1 Cr (FY25) → +54.3% - PAT Margin improved accordingly.

What is Sudarshan Pharma Industries Ltd share price analysis?

Sudarshan Pharma Industries Ltd currently shows a neutral. The stock trades at a P/E of 39.4 with a market cap of ₹990 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sudarshan Pharma Industries Ltd planning capital expenditure?

Nutraceuticals Plant project with a cost of Rs. 2.5 Cr and machinery cost of Rs. 1.15 Cr (2019-2020).

Keep Sudarshan Pharma Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.